Coronavirus Disease 2019-Associated Coagulopathy

Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently found to suffer from both arterial and venous thrombotic events due to the perpetuation of a hypercoagulable state. This phenomenon, termed COVID-19-associated coagulopathy, is now considered a major component...

Full description

Saved in:
Bibliographic Details
Published in:Mayo Clinic proceedings Vol. 96; no. 1; p. 203
Main Authors: Lippi, Giuseppe, Sanchis-Gomar, Fabian, Favaloro, Emmanuel J, Lavie, Carl J, Henry, Brandon M
Format: Journal Article
Language:English
Published: England 01.01.2021
Subjects:
Blood Coagulation Disorders - etiology
Blood Coagulation Disorders - physiopathology
COVID-19 - complications
COVID-19 - physiopathology
Disease Progression
Humans
SARS-CoV-2
ISSN:1942-5546, 1942-5546
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently found to suffer from both arterial and venous thrombotic events due to the perpetuation of a hypercoagulable state. This phenomenon, termed COVID-19-associated coagulopathy, is now considered a major component of the pathophysiology of this novel infectious disease, leading to widespread thrombosis. While at first, the vascular insults may be limited to the pulmonary microvasculature, as the disease progresses, systemic involvement occurs, culminating in distant organ thrombosis and multiorgan dysfunction syndrome. In this review article, we discuss recent insights into the pathophysiologic mechanisms of COVID-19-associated coagulopathy and review the clinical, histopathologic, and laboratory evidence, which leads us to conclude that COVID-19 is both a pulmonary and vascular disorder.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1942-5546
1942-5546
DOI:10.1016/j.mayocp.2020.10.031